{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:20:41Z","timestamp":1788225641279,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02756-5","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T10:15:19Z","timestamp":1766744119000},"page":"689-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic and renal effects of combined SGLT-2 inhibitors and GLP1-R agonists therapy in type 2 diabetes: a real-world analysis across DKD and non-DKD patients"],"prefix":"10.1007","volume":"49","author":[{"given":"L.","family":"Mazzeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2413-2388","authenticated-orcid":false,"given":"S.","family":"Wolde Sellasie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pecchioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Di Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zaccaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sperti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Giurato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Della-Morte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Caprio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bellia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Uccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"2756_CR1","doi-asserted-by":"publisher","unstructured":"Marx N et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes, Eur Heart J\u00a044(39)\u00a04043\u20134140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192","DOI":"10.1093\/eurheartj\/ehad192"},{"key":"2756_CR2","doi-asserted-by":"publisher","unstructured":"ElSayed NA et al (2025) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142025, Diabetes Care, vol. 48, no. Supplement_1, pp. S181\u2013S206.\u00a0https:\/\/doi.org\/10.2337\/dc25-S009","DOI":"10.2337\/dc25-S009"},{"key":"2756_CR3","doi-asserted-by":"publisher","unstructured":"Arnold SV et al (Dec. 2022) Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER. BMC Endocr Disord 22(1):111. https:\/\/doi.org\/10.1186\/s12902-022-01026-2","DOI":"10.1186\/s12902-022-01026-2"},{"key":"2756_CR4","doi-asserted-by":"publisher","unstructured":"Antonazzo IC et al (2024) Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database, Acta Diabetol, 62(3), pp. 343\u2013351, Aug. https:\/\/doi.org\/10.1007\/s00592-024-02359-1","DOI":"10.1007\/s00592-024-02359-1"},{"key":"2756_CR5","doi-asserted-by":"publisher","unstructured":"Bonora E et al (2021) Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory, Nutrition, Metabolism and Cardiovascular Diseases, vol. 31, no. 9, pp. 2661\u20132668, Aug. https:\/\/doi.org\/10.1016\/j.numecd.2021.06.006","DOI":"10.1016\/j.numecd.2021.06.006"},{"key":"2756_CR6","doi-asserted-by":"publisher","unstructured":"Moreno Juste A et al (Aug. 2019) Treatment patterns of diabetes in italy: A Population-Based study. Front Pharmacol 10. https:\/\/doi.org\/10.3389\/fphar.2019.00870","DOI":"10.3389\/fphar.2019.00870"},{"key":"2756_CR7","doi-asserted-by":"publisher","unstructured":"Badve SV et al (Jan. 2025) Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 13(1):15\u201328. https:\/\/doi.org\/10.1016\/S2213-8587(24)00271-7","DOI":"10.1016\/S2213-8587(24)00271-7"},{"key":"2756_CR8","doi-asserted-by":"publisher","unstructured":"Spiazzi BF et al (Dec. 2024) SGLT2 inhibitors, cardiovascular outcomes, and mortality across the spectrum of kidney disease: A systematic review and meta-analysis. Diabetes Res Clin Pract 218:111933. https:\/\/doi.org\/10.1016\/j.diabres.2024.111933","DOI":"10.1016\/j.diabres.2024.111933"},{"key":"2756_CR9","doi-asserted-by":"publisher","unstructured":"Lunati ME et al (Jan. 2024) Type 2 diabetes mellitus Pharmacological remission with Dapagliflozin plus oral semaglutide. Pharmacol Res 199:107040. https:\/\/doi.org\/10.1016\/j.phrs.2023.107040","DOI":"10.1016\/j.phrs.2023.107040"},{"issue":"11","key":"2756_CR10","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.62347\/MCEE4840","volume":"16","author":"Y Wu","year":"2024","unstructured":"Wu Y, Yang Z, Cao Q (2024) Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis. Am J Transl Res 16(11):6852\u20136866. https:\/\/doi.org\/10.62347\/MCEE4840","journal-title":"Am J Transl Res"},{"issue":"Supplement_1","key":"2756_CR11","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.2337\/dc25-S006","volume":"48","author":"NA ElSayed","year":"2025","unstructured":"ElSayed NA et al (2025) 6. Glycemic goals and hypoglycemia: standards of care in diabetes\u20142025. Diabetes Care 48(Supplement_1):S128\u2013S145. https:\/\/doi.org\/10.2337\/dc25-S006","journal-title":"Diabetes Care"},{"issue":"5","key":"2756_CR12","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer IH et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 102(5):974\u2013989. https:\/\/doi.org\/10.1016\/j.kint.2022.08.012","journal-title":"Kidney Int"},{"issue":"12","key":"2756_CR13","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2169\/internalmedicine.4323-19","volume":"59","author":"K Nonomura","year":"2020","unstructured":"Nonomura K, Iizuka K, Kuwabara-Ohmura Y, Yabe D (2020) SGLT2 inhibitor and GLP-1 receptor agonist combination therapy substantially improved the renal function in a patient with type 2 diabetes: implications for additive renoprotective effects of the two drug classes. Intern Med 59(12):1535\u20131539. https:\/\/doi.org\/10.2169\/internalmedicine.4323-19","journal-title":"Intern Med"},{"issue":"19","key":"2756_CR14","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"issue":"22","key":"2756_CR15","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"2","key":"2756_CR16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.clinthera.2019.12.012","volume":"42","author":"O D\u00edaz-Trastoy","year":"2020","unstructured":"D\u00edaz-Trastoy O et al (2020) GLP1 receptor agonist and SGLT2 inhibitor combination: an effective approach in real-world clinical practice. Clin Ther 42(2):e1\u2013e12. https:\/\/doi.org\/10.1016\/j.clinthera.2019.12.012","journal-title":"Clin Ther"},{"issue":"1","key":"2756_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02737-1","volume":"24","author":"N Chaiyakunapruk","year":"2025","unstructured":"Chaiyakunapruk N, Tan X, Liang Y, Guevarra M, Xie L, Cheng AYY (2025) Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes. Cardiovasc Diabetol 24(1):177. https:\/\/doi.org\/10.1186\/s12933-025-02737-1","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2756_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01798-4","volume":"22","author":"P Gourdy","year":"2023","unstructured":"Gourdy P, Darmon P, Dievart F, Halimi J-M, Guerci B (2023) Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol 22(1):79. https:\/\/doi.org\/10.1186\/s12933-023-01798-4","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2756_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK et al (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes. JAMA Cardiol 6(2):148. https:\/\/doi.org\/10.1001\/jamacardio.2020.4511","journal-title":"JAMA Cardiol"},{"key":"2756_CR20","doi-asserted-by":"publisher","unstructured":"The EMPA-KIDNEY, Collaborative Group (2023) Empagliflozin in Patients with Chronic Kidney Disease, New England Journal of Medicine, vol. 388, no. 2, pp. 117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","DOI":"10.1056\/NEJMoa2204233"},{"key":"2756_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera FB et al (2024) Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol 18:100679. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100679","journal-title":"Am J Prev Cardiol"},{"issue":"2","key":"2756_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12020183","volume":"12","author":"I Caruso","year":"2022","unstructured":"Caruso I et al (2022) Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies. Metabolites 12(2):183. https:\/\/doi.org\/10.3390\/metabo12020183","journal-title":"Metabolites"},{"issue":"1","key":"2756_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"V Vallon","year":"2021","unstructured":"Vallon V, Verma S (2021) Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol 83(1):503\u2013528. https:\/\/doi.org\/10.1146\/annurev-physiol-031620-095920","journal-title":"Annu Rev Physiol"},{"issue":"10365","key":"2756_CR24","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"C Baigent","year":"2022","unstructured":"Baigent C et al (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400(10365):1788\u20131801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8","journal-title":"Lancet"},{"key":"2756_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111743","volume":"213","author":"G Russo","year":"2024","unstructured":"Russo G et al (2024) The quality of care in type 1 and type 2 diabetes \u2013 a 2023 update of the AMD annals initiative. Diabetes Res Clin Pract 213:111743. https:\/\/doi.org\/10.1016\/j.diabres.2024.111743","journal-title":"Diabetes Res Clin Pract"},{"key":"2756_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-024-02423-w","author":"S Wolde Sellasie","year":"2025","unstructured":"Wolde Sellasie S et al (2025) Attending an integrated nephrology and diabetology outpatient service can improve diabetic kidney disease treatment: a single-center experience. Acta Diabetol. https:\/\/doi.org\/10.1007\/s00592-024-02423-w","journal-title":"Acta Diabetol"},{"issue":"38","key":"2756_CR27","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW et al (2024) 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 45(38):3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178","journal-title":"Eur Heart J"},{"key":"2756_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"F Mach","year":"2019","unstructured":"Mach F et al (2019) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 290:140\u2013205. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.08.014","journal-title":"Atherosclerosis"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02756-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02756-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02756-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:17:45Z","timestamp":1774415865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02756-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["2756"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02756-5","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Informed consent was not required in accordance with the Italian regulation for non-interventional (observational) retrospective studies concerning human beings (AIFA Guidelines for Observational Studies, see www.AIFA.gov).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}